Summary
An experimental personalized mRNA vaccine is showing encouraging results in the fight against melanoma, one of the deadliest forms of skin cancer. Moderna and Merck tested the vaccine with Keytruda in more than 1,100 high-risk patients whose tumors had been surgically removed. Researchers created each vaccine from the patient’s tumor and used artificial intelligence to identify mutations that could help train the immune system to recognize and attack cancer cells. The Phase 3 trial found that patients receiving the vaccine combination remained cancer-free longer and faced a lower risk of melanoma returning or spreading. The findings could mark a significant advance in personalized cancer treatment.
CBS News
